• News
  • Toyobo to market RNA Analysis Kit based on RIKEN technology to help develop genomic medicine

Toyobo to market RNA Analysis Kit based on RIKEN technology to help develop genomic medicine

Sep 17, 2019 Products

Download PDF ( 261KB )

Toyobo Co., Ltd. has productized a ribonucleic acid (RNA) analysis kit based on a novel system titled RamDA-seqTM*1, that allows full-length sequencing of the total RNA of a single cell. The Laboratory for Bioinformatics Research at the RIKEN Center for Biosystems Dynamics Research developed this method last year.


RNA Analysis Kit

RNA Analysis Kit


As national health insurance programs in Japan have covered genomic medicine since June 2019, medical care is progressing to be tailored to individual patients by selecting suitable treatment and drugs after analyzing a patient’s genes. In recent years, genetic information in a single cell has proven to be effective in treating diseases such as cancer caused by gene mutations, because each cell has different genetic properties. However, conventional methods have been unable to reliably detect disease-causing mutations from an extremely small amount of RNA*2 derived from a single cell.

RIKEN, which is based in Wako City, Saitama Prefecture, is one of Japan's largest scientific research institutes. RIKEN has developed a novel method, RamDA-seqTM, which enables the amplification of RNA in low bias and the detection of an expression level of genes in a single cell. This method allows the comprehensive identification of RNA varieties and their amounts in a single cell. It drastically improved the analytical precision of a disease-causing gene expression level and mutations in various RNAs, including non-polyadenylated RNAs whose functions remain unclear due to the difficulty in their detection.

RNA Analysis Kit, which Toyobo productized under RIKEN’s technological guidance, consists of reagents and a user manual necessary to conduct RamDA-seqTM. The kit makes it possible to prepare samples more smoothly and stably, as described in articles published by RIKEN.

The kit is expected to expand the use of RamDA-seqTM, to accelerate the development of various medical fields ranging from basic research to regenerative and genomic medicine. Toyobo will launch the product for research institutes including pharmaceutical companies developing drugs for cancer and other diseases on September 30, 2019. The company aims to achieve annual sales of \1 billion in fiscal 2022.

■RNA Analysis Kit to be marketed

・cDNA preparation kit for next-generation sequencer analysis “GenNext®RamDA-seqTM Single Cell Kit”
 ¥118,000 (for 24 uses), ¥398,000 (for 96 uses)
・cDNA preparation kit for real-time polymerase chain reaction (PCR) analysis “RT-RamDATM cDNA Synthesis Kit”
 ¥59,000 (for 24 uses), ¥198,000 (for 96 uses)

※1 RIKEN press release “Researchers successfully sequence total RNA of single cells”
http://www.riken.jp/en/pr/press/2018/20180306_1/ (March 6, 2018)

※2 RNA, genome and genes

Genome includes a complete set of genetic information of the cell, which is recorded as sequences of four types of nucleotide in a biological polymer called DNA. Genes are regions that record genetic information in genome. Genetic information is read out by synthesizing RNA using DNA as a template.

The cells that constitute our bodies control its gene expression to perform various functions, while having almost the same genetic information. Since this gene expression is mediated by molecules called RNA, a comprehensive analysis of RNA is effective in understanding the individual characters of individual cells.

For more information, contact

Corporate Communication Department, Toyobo Co., Ltd.


Cautionary Statement

This website contains forward-looking statements that reflect Toyobo's plans and expectations. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause Toyobo's actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.